



New-to-Market Medical Pharmacy Products Currently Under Clinical Review by Medica

Updated 10/5/2024

Brand name	Generic name	J code	National Drug Codes (NDCs)	Date of FDA approval
Ebglyss	lebrikizumab-lbkz	J9999	00002-7772-11, 00002-7797-11	September 13, 2024
Kisunla	donanemab-azbt	J3590	00002-9401-01	July 2, 2024
Lymphir	denileukin diftitox-cxdl	J9999	52658-7777-01	August 7, 2024
Niktimvo	axatilimab-csfr	J3590	50881-0012-10	August 14, 2024
Ocrevus Zunovo	ocrelizumab; hyaluronidase-ocsq	J3590	50242-0554-01	September 13, 2024
Piasky	crovalimab-akkz	J3590	50242-0115-01	June 20, 2024
Tecelra	afamitresgene autoleucel	J9999	83205- 0001-02	August 1, 2024
Tecentriq Hybreza	Atezolizumab; hyaluronidase-tqjs	J9999	50242-0933-01	September 12, 2024
Tremfya IV	guselkumab	J3590	Multiple	September 11, 2024

Note: Drugs recently removed from this list have been addressed under new [Medica drug management policies](#).

This list is provided for our provider network's convenience and information. While this list is intended to be comprehensive, the U.S. Food and Drug Administration (FDA) approval process and its timing are outside of Medica's control. Medica reserves the right to adjust claims for any new-to-market medical pharmacy products as discussed in [the New-to-Market Medical Pharmacy Products coverage policy](#).